在MASLD和MASH肝硬化中药物重定向:基于途径分析的目标和治疗方法
Carlos J Pirola1, Silvia Sookoian2
1Systems Biology of Complex Diseases, Centro de Investigación Traslacional en Salud, Universidad Maimónides, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Progress in molecular biology and translational science
|June 28, 2024
概括
对代谢功能障碍相关的脂肪肝炎 (MASH) - 肝硬化的新药标的鉴定是复杂的. 这项研究揭示了MASH和肝硬化重叠的分子过程和独特的机制,突出了免疫反应,细胞循环和表观遗传调节作为关键的治疗点.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 系统生物学 系统生物学
- 药物发现 药物发现 药物发现
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) - 肝硬化呈现出复杂的,叠加的表型.
- 独特的病理生理机制是MASH和肝硬化的基础,使目标识别复杂化.
研究的目的:
- 使用系统生物学方法预测MASH肝硬化治疗的可用药物途径.
- 阐明MASH和肝硬化的共同和独特的分子机制.
主要方法:
- 采用了基因/蛋白质和集丰富分析.
- 系统生物学建模被用来分析疾病机制.
- 路径分析确定了涉及的关键生物过程.
主要成果:
- 马氏硬化病原发生涉及多个重叠的分子过程.
- 系统生物学证实了MASH和肝硬化之间的独特和共同的疾病机制.
- 发现的关键途径包括免疫反应调节,细胞周期控制和表观遗传调节.
结论:
- 对MASH肝硬化的治疗策略需要对潜在的生物过程有深入的了解.
- 对于MASH与MASH肝硬化,可能需要明确的分子标.
- 未来的疗法应该考虑MASH肝硬化中的自然史和渐进性肝损伤.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Cirrhosis II: Pathophysiology
49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49


